Publicação: 17 de agosto de 2020
Encouraging results from phase 1/2 COVID-19 vaccine trials (Comment)Bar-Zeev, J MossLancetVol 396 August 15, 2020 448-449 Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti*, Katie J Ewer*, Parvinder K Aley et al.LancetVol 396 August 15, 2020 467-478 Immunogenicity and safety of […]
Encouraging results from phase 1/2 COVID-19 vaccine trials (Comment)
Bar-Zeev, J MossLancet
Vol 396 August 15, 2020 448-449
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M Folegatti*, Katie J Ewer*, Parvinder K Aley et al.Lancet
Vol 396 August 15, 2020 467-478
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebocontrolled, phase 2 trial
Feng-Cai Zhu*, Xu-Hua Guan*, Yu-Hua Li et al.Lancet
Vol 396 August 15, 2020 479-488
